Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Review Article

Targeting the C-MET/HGF Signaling Pathway in Pancreatic Ductal Adenocarcinoma

Author(s): Sadaf Ghanaatgar-Kasbi, Shadi Khorrami, Amir Avan*, Seyed A. Aledavoud and Gordon A. Ferns*

Volume 24 , Issue 39 , 2018

Page: [4619 - 4625] Pages: 7

DOI: 10.2174/1381612825666190110145855

Price: $65

Abstract

The c-mesenchymal-epithelial transition factor (c-MET) is involved in the tumorigenesis of various cancers. HGF/Met inhibitors are now attracting considerable interest due to their anti-tumor activity in multiple malignancies such as pancreatic cancer. It is likely that within the next few years, HGF/Met inhibitors will become a crucial component for cancer management. In this review, we summarize the role of HGF/Met pathway in the pathogenesis of pancreatic cancer, with particular emphasize on HGF/Met inhibitors in the clinical setting, including Cabozantinib (XL184, BMS-907351), Crizotinib (PF-02341066), MK-2461, Merestinib (LY2801653), Tivantinib (ARQ197), SU11274, Onartuzumab (MetMab), Emibetuzumab (LY2875358), Ficlatuzumab (AV- 299), Rilotumumab (AMG 102), and NK4 in pancreatic cancer.

Keywords: c-mesenchymal-epithelial transition factor, HGF/Met inhibitors, pancreatic cancer, tumorigenesis, anti-tumor activity.


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy